GlassScriptPhysician profile
Jonathan Edward Maccabe
NPI 1790739654
$3,218.08
in general payments reported to CMS, 2019-2025
28 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $175 · 2021: $319 · 2022: $87.12 · 2023: $257 · 2024: $720 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $746.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $399.99 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $304.42 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Amgen INC. | $299.60 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $246.62 | 2019-2024 | Xarelto |
| Pfizer INC. | $134.29 | 2019-2024 | |
| Medtronic, INC. | $134.23 | 2022-2024 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.50 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $81.30 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.02 | 2019-2024 | Jardiance |
| Chiesi USA, INC. | $67.09 | 2021 | |
| Astellas Pharma US INC | $64.80 | 2019-2021 | |
| Biotronik INC. | $64.45 | 2019-2025 | Acticor 7 Vr-T Dx |
| Cvrx, INC. | $54.95 | 2021-2024 | Barostim Neo System |
| Philips North America LLC | $48.98 | 2025 | Ecc Solutions, Ambulatory Monitoring & Diagnostics Undivided |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $48.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $45.73 | 2019-2020 | |
| Abbott Laboratories | $44.08 | 2024 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $43.47 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $39.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $33.43 | 2019 | |
| Atricure, INC. | $32.76 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Inspire Medical Systems, INC. | $30.16 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $20.08 | 2019 | |
| Irhythm Technologies, INC. | $19.91 | 2022 | |
| Amarin Pharma, INC. | $16.69 | 2019 | |
| Cardinal Health 414 LLC | $16.01 | 2019 | |
| Medtronic Vascular, INC. | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Maccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.